Identification of biomarker for ovarian cancer by serum proteomic analysis using SELDI-ToF-MS.
- Author:
Chul Min LEE
1
;
Soon Beom KANG
;
Yong Kyoon CHO
;
Hoon CHOI
;
Bok Rin KIM
Author Information
1. Department of Obstetrics and Gynecology, Inje University Sanggye Paik Hospital, Korea. morula@chol.com
- Publication Type:Original Article
- Keywords:
SELDI-ToF-MS;
Ovarian cancer;
Biomarker;
Proteomics;
Bioinformatics
- MeSH:
Biomarkers;
Computational Biology;
Decision Trees;
Humans;
Mass Spectrometry;
Ovarian Neoplasms*;
Proteomics;
Sensitivity and Specificity;
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization*
- From:Korean Journal of Gynecologic Oncology
2006;17(2):147-156
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: SELDI-ToF-MS is an affinity-based mass spectrometric method. This study was performed to determine feasibility of serum proteomic pattern analysis using SELDI-ToF-MS for the detection of ovarian cancer. METHODS: Forty-three epithelial ovarian cancer patients and seventy-seven controls were included in the study from October 2003 to March 2005 in Sanggye Paik Hospital. Potential tumor biomarkers in sixty serum samples were screened, including twenty-one ovarian cancers and thirty-nine controls. Proteomic pattern was analyzed by SELDI-ToF-MS and optimal discriminating m/z value with proper cutoff of log-normalized intensity was determined by decision tree analysis (Phase I). Another sixty serum samples were obtained from twenty-two ovarian cancers and thirty-eight controls. Through analysis using SELDI-ToF-MS, the performance of diagnosing ovarian cancer was determined by applying previously adopted cutoff log-normalized intensity of m/z value determined in Phase I experiment (Phase II). RESULTS: A biomarker of 3501.23 kDa was selected based on the collective contribution to the optimal separation between ovarian cancers and controls. Sensitivity of 90.9% and specificity of 84.2% was achieved by SELDI-ToF-MS in Phase II experiment. Age, stage, and histologic type did not affect performance of SELDI-ToF-MS for diagnosing ovarian cancer. CONCLUSION: Serum proteomic analysis by biochip and mass spectrometry is a feasible method in diagnosing ovarian cancer.
